Chelby Jessica Wakefield, MD

My care philosophy is rooted in compassion, clarity, and the belief that science and empathy must go hand in hand. As an oncologist specializing in stem cell transplantation and leukemias, I see my role not only as a physician but as a guide and anchor for patients and their families during one of the most challenging and uncertain times in their lives. I am deeply motivated by the science that drives progress in cancer care, but even more by the people it serves. In every appointment, my goals are simple but essential: that my patients understand their diagnosis, that they know the next step in their journey, and that they feel confident in their treatment plan. Above all, I want every person who sits across from me to feel supported, informed, and never alone in facing what comes next.

Keywords hepatosplenic t-cell lymphoma, cancer clinical trials, multiple myeloma with bone involvement, inherited hematologic malignancies, minimal residual disease, bone marrow stimulation, immune therapy, hydroxyurea therapy, t-cell prolymphocytic leukemia, follicular t-cell lymphoma, mixed phenotype acute leukemia (mpal), flt3 mutation, chronic neutrophilic leukemia, bone marrow fibrosis, bone marrow harvest, refractory anemia with excess blasts, idh 1 mutation, aplastic anemia, adult t cell lymphoma, leukemia genomics, lymphedema physical therapy, chemotherapy iv infusion, rectal neuroendocrine tumor, neuroendocrine carcinoma, metastatic neuroendocrine tumors, relapsed myeloma, colon adenocarcinoma, adjuvant chemotherapy, neutrophilia, elevated transferrin saturation, elevated ferritin, upper extremity lymphedema, large cell neuroendocrine tumors, metastatic blood cancers, neuroendocrine tumor of the lung, generalized lymphatic anomaly, adenocarcinoma of the bladder, hormone receptor negative breast cancer, nut carcinoma, fibrolamellar carcinoma, ductal carcinoma in situ (dcis), personal history of cancer, secondary cancer screening, long term side effects of cancer treatment, personal history of radiation therapy, personal history of chemotherapy, blood cancer chemotherapy, autoimmune neutropenia (ain), evans syndrome, hemophilia inhibitors, factor thirteen deficiency, factor seven deficiency, hereditary elliptocytosis (he), acquired elliptocytosis, prostate cancer chemotherapy, bladder cancer chemotherapy, testicular cancer chemotherapy, relapsed acute myelogenous leukemia (aml), adolescent and young adult cancer (aya), breast cancer biological targeted therapy, relapsed non hodgkin lymphoma, relapsed hodgkin lymphoma, relapsed acute lymphoblastic leukemia (all), neutrophil disorders, blastic plasmacytoid dendritic cell neoplasm, disseminated intravascular coagulation, hormone receptor positive breast cancer, her2 positive breast cancer, carcinoma of unknown primary, lymphomatoid granulomatosis, intrathecal chemotherapy, maintenance chemotherapy, consolidation chemotherapy, induction chemotherapy, er negative breast cancer, pituitary cancer, chronic myelomonocytic leukemia, malignant adnexal tumor, peripheral t cell lymphoma, intraarterial chemotherapy of tumors, inflammatory breast cancer, recurrent breast cancer, brain metastases, coagulation disorders, bone marrow failure syndromes, waldenstrom macroglobulinemia, liver metastases, adrenal nodules, metastatic breast cancer, hodgkin lymphoma, triple negative breast cancer, cancer genetics, hemoglobinopathies, breast cancer therapy, thrombocytosis, castleman's disease, acute blood loss anemia, blood disorders, lymphopenia, prostate cancer.